The fixed combination of fortified vancomycin and amikacin ophthalmic solution-VA solution - In vitro study of the potency and stability

CMUR > China Medical University Hospital > Jurnal articles > Item 310903500/30200

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/30200

Title:	The fixed combination of fortified vancomycin and amikacin ophthalmic solution-VA solution - In vitro study of the potency and stability
Authors:	Lin, JM;Tsai, YY;Fu, YL
Contributors:	附設醫院眼科部;China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan;Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan
Date:	2005
Issue Date:	2010-09-24 14:51:00 (UTC+8)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Abstract:	beta-catenin is upregulated in many human cancers and considered to be an oncogene. Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies, and individuals who are chronic hepatitis B virus (HBV) carriers have a greater than 100-fold increased relative risk of developing HCC. Here we report a mechanism by which HBV-X protein (HBX) upregulates beta-catenin. Erk, which is activated by HBX, associates with GSK-3 beta through a docking Motif ((FKFP)-F-291) of GSK-3 beta and phosphorylates GSK-3 beta at the (43)Thr residue, which primes GSK-3 beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3 beta and upregulation of P-catenin. This pathway is a general signal, as it was also observed in cell lines in which Erk-primed inactivation of GSK-3 beta was regulated by IGF-1, TGF-beta, and receptor tyrosine kinase HER2, and is further supported by immunohistochemical staining in different human tumors, including cancers of the liver, breast, kidney, and stomach.
Relation:	CORNEA 24(6):717-721
Appears in Collections:	[China Medical University Hospital] Jurnal articles

Files in This Item:

There are no files associated with this item.

Loading...